May. 31 at 5:32 PM
$CLRB Once a drug reaches a global revenue potential of around
$1 billion, it achieves "blockbuster" status within the pharmaceutical industry. This exact potential in the 2nd-line setting is the primary reason why Cellectar secured its massive
$140 million financing package in May 2026. Investors are explicitly funding the Phase 3 confirmatory trial starting in Q4 2026, which is strategically designed to legally secure and expand the drug's label into this earlier 2nd-line treatment window. 🔥🔥🔥🔥🔥🔥🔥🔥🔥
